AEM vs AUGO

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

The deterministic health scores raise significant concerns, with a Piotroski F-Score of 4/9 indicating marginal financial health and no available Altman Z-Score to confirm safety from distress. Despite strong revenue growth and high operating margins, the company reports negative profit margins and ROE, alongside a dangerously high payout ratio of 780%, suggesting dividends are unsustainable. The stock trades at a steep valuation premium with a Price/Book of 17.69 and Forward P/E of 12.98, while recent earnings have consistently missed estimates—0 out of the last 4 beats and an average surprise of -86.59%. Although analyst consensus is 'strong_buy', price momentum appears disconnected from fundamentals, increasing downside risk.